Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 75% Improvement Relative Risk ICU admission 29% Hospitalization 67% Razonable et al. Casirivimab/i.. for COVID-19 EARLY Is early treatment with casirivimab/imdevimab beneficial for COVID-19? Retrospective 1,392 patients in the USA (December 2020 - April 2021) Lower hospitalization with casirivimab/imdevimab (p=0.0011) Razonable et al., EClinicalMedicine, doi:10.1016/j.eclinm.2021.101102 Favors casirivimab/im.. Favors control
Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
Razonable et al., EClinicalMedicine, doi:10.1016/j.eclinm.2021.101102
Razonable et al., Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients.., EClinicalMedicine, doi:10.1016/j.eclinm.2021.101102
Oct 2021   Source   PDF  
  All Studies   Meta
Retrospective 696 patients treated with casirivimab/imdevimab, and 696 matched controls, showing lower hospitalization with treatment. Authors only included patients with documented followup, which is likely to disproportionately bias the control group towards patients with worse outcomes.
Confounding by treatment propensity. This study analyzes a population where only a fraction of eligible patients received the treatment. Patients receiving treatment may be more likely to follow other recommendations, more likely to receive additional care, and more likely to receive adjuvant treatments that are not tracked in the data (e.g., nasal/oral hygiene [, (B)], vitamin D [ (C)], etc.) — either because the physician recommending casirivimab/imdevimab also recommended them, or because the patient seeking out casirivimab/imdevimab is more likely to be familiar with the efficacy of additional treatments. Therefore, these kind of studies may overestimate the efficacy of treatments. .
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan].
risk of death, 75.0% lower, RR 0.25, p = 0.37, treatment 1 of 696 (0.1%), control 4 of 696 (0.6%), NNT 232.
risk of ICU admission, 28.6% lower, RR 0.71, p = 0.77, treatment 5 of 696 (0.7%), control 7 of 696 (1.0%), NNT 348.
risk of hospitalization, 66.7% lower, RR 0.33, p = 0.001, treatment 11 of 696 (1.6%), control 33 of 696 (4.7%), NNT 32.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Razonable et al., 31 Oct 2021, retrospective, USA, peer-reviewed, 18 authors, study period 4 December, 2020 - 9 April, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Abstract: EClinicalMedicine 40 (2021) 101102 Contents lists available at ScienceDirect EClinicalMedicine journal homepage: Research paper CasirivimabImdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19 Raymund R. Razonablea,*, Colin Pawlowskib, John C. O’Horoa, Lori L. Arndtc, Richard Arndtc, Dennis M. Bierlea, Molly Destro Borgena, Sara N. Hansond, Michelle C. Hedina, Patrick Lenehanb, Arjun Puranikb, Maria T Sevillee, Leigh L. Speicherf, Sidna M. Tulledge-Scheitela, AJ Venkatakrishnanb, Caroline G. Wilkerg, Andrew D. Badleya, Ravindra Ganesha a Mayo Clinic, Rochester, MN, United States nFerence, Cambridge, MA, United States c Mayo Clinic Health System, Eau Claire, WI, United States d Mayo Clinic Health System, Mankato, MN, United States e Mayo Clinic in Arizona, Phoenix, United States f Mayo Clinic in Florida, Jacksonville, United States g Mayo Clinic Health System Franciscan Healthcare, La Crosse, WI, United States b A R T I C L E I N F O Article History: Received 5 July 2021 Revised 10 August 2021 Accepted 11 August 2021 Available online 30 August 2021 Keywords: Monoclonal antibodies Casirivimab Imdevimab Covid-19 Outcomes A B S T R A C T Background: Real-world clinical data to support the use of casirivimabimdevimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. This study aimed to assess the outcomes of casirivimabimdevimab treatment of mild to moderate COVID-19. Methods: A retrospective cohort of 696 patients who received casirivimabimdevimab between December 4, 2020 and April 9, 2021 was compared to a propensity-matched control of 696 untreated patients with mild to moderate COVID-19 at Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin. Primary outcome was rate of hospitalization at days 14, 21 and 28 after infusion. Findings: The median age of the antibody-treated cohort was 63 years (interquartile range, 5271); 45¢5% were 65 years old; 51.4% were female. High-risk characteristics were hypertension (52.4%), body mass index 35 (31.0%), diabetes mellitus (24.6%), chronic lung disease (22.1%), chronic renal disease (11.4%), congestive heart failure (6.6%), and compromised immune function (6.7%). Compared to the propensitymatched untreated control, patients who received casirivimabimdevimab had significantly lower all-cause hospitalization rates at day 14 (1.3% vs 3.3%; Absolute Difference: 2.0%; 95% confidence interval (CI): 0.53.7%), day 21 (1.3% vs 4.2%; Absolute Difference: 2.9%; 95% CI: 1.24.7%), and day 28 (1.6% vs 4.8%; Absolute Difference: 3.2%; 95% CI: 1.45.1%). Rates of intensive care unit admission and mortality at days 14, 21 and 28 were similarly low for antibody-treated and untreated groups. Interpretation: Among high-risk patients with mild to moderate COVID-19, casirivimabimdevimab treatment was associated with a significantly lower rate of hospitalization. Funding: Mayo Clinic. © 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop